A carregar...

Predicting Cross Reactive Immunological Material (CRIM) Status in Pompe Disease Using GAA Mutations: Lessons Learned from 10 Years of Clinical Laboratory Testing Experience

Enzyme replacement therapy (ERT) for Pompe disease using recombinant acid alpha-glucosidase (rhGAA) has resulted in increased survival although the clinical response is variable. Cross Reactive Immunological Material (CRIM)-negative status has been recognized as a poor prognostic factor. CRIM-negati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bali, Deeksha S., Goldstein, Jennifer L., Banugaria, Suhrad, Dai, Jian, Mackey, Joanne, Rehder, Catherine, Kishnani, Priya S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3278076/
https://ncbi.nlm.nih.gov/pubmed/22252923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajmg.c.31319
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!